Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: gg cox who wrote (41)	3/11/2004 5:13:38 PM
From: gg cox	Read Replies (1) \| Respond to of 66

""""I like the part at minute 7 where Dr. Norton states that CH123/PreVu is the only test available that can predict who or who will not have a heart attack or stroke. We've come a long way differentiating ourselves from a simple cholesterol test thanks to McNeil. The tape test has moved into 'larger scale production' to meet clinical trial and insurance testing requirements. Because the tape test targets labs and insurance markets we do not need FDA approval to sell in the USA. My gut feeling is that the product is already in the USA undergoing pre marketing of some kind. The home test sounds like it has evolved beyond the wallet test to something more user friendly. 2005. Lungalert is the only lung cancer test available. It is involved in the Elcap study with 1000 souls. Elcap will definitively determine if lungalert is effective and to what degree. Because there are no comparative products available it is believed lungalert may move quickly through the regulatory process and may leap ahead of Cholorectalert in 2005. Breastalert is moving forward. MD Anderson has moved into clinical trials and 'Louisville' a private US breast cancer clinic has started trials. Burn rate is steady at $900,000 per quarter. CH123: Prevu Accreditation by OHIP 2004 CH123: Japanese Approval 2004 CH123: McNeil to launch CH123 2004 CH123: Announcement of World Wide, European or US Partners 2004 ColorectAlert: Canadian Approval 2004 ColorectAlert: FDA trials commence 2005 LungAlert: Canadian Approval 2004 LungAlert: FDA trials commence 2005 BreastAlert: expanded trials to report 2004/5 Cancer Suite: US and EU Development Partners 2005 AtheroGenics Phase II ARISE Trial due Q4 2004-5 Home Tests under development: 2005 Elcap to report 2004/5 """"" stockhouse.com;